KRSNAA

- Krsnaa Diagnostics issued a Corrigendum to its Postal Ballot Notice dated August 13, 2026, as requested by NSE. This provides additional details for the proposed preferential issue of 16,21,000 share warrants to Promoter and Promoter Group members. The aggregate shareholding of the Promoter and Promoter Group will increase from 27.11% to 29.70% post-issue (fully diluted basis).

- Krsnaa Diagnostics received an order from the Income Tax Dept. on Aug 14, 2026, for AY 2022-23. - The order rectifies tax computation, resulting in a differential/additional demand of ₹12,09,98,110/-. - The company will file an appeal/rectification against this demand.

- Krsnaa Diagnostics Ltd. announced a preferential issue of up to 16,21,000 Warrants for ₹91,74,86,000/-. - Each Warrant is priced at ₹566/- and is convertible into one equity share (face value ₹5) within 18 months from allotment. - The Warrants will be allotted to Mr. Rajendra Mutha and Krsnaa Diagnostics (Mumbai) Private Limited.

- Q1 FY27 revenue grew approximately 22% YoY, with like-to-like projects growing 12% and retail business growing 64% YoY. - EBITDA margin compressed to 25% from 27% YoY due to upfront costs for new project implementations (e.g., Rajasthan manpower onboarding), but is expected to become EBITDA positive by Q2 and reach double digits by year-end. - Rajasthan PPP project's Q1 FY27 revenue was ₹26 Cr, expected to double in Q2, with an annualized expectation of ₹100-150 Cr for FY27. - The company was awarded the Himachal Pradesh CT project (34 CT scans) and operationalized 8 MRI centers in Maharashtra. - Receivables from Himachal Pradesh and Karnataka are being addressed, with funds flowing in/allocated and expected recovery by Q2. - Promoters infused funds via warrants for capital expenditure and potential acquisitions. - Management's focus for coming quarters is on execution, utilization, profitability, and sustainable growth.

- Krsnaa Diagnostics Limited issued a Postal Ballot notice for approval to issue up to 16,21,000 Warrants convertible into Equity Shares on a preferential basis to its Promoter and Promoter Group. - The issue price is Rs. 566/- per Warrant, aggregating up to Rs. 91.75 crore. - E-voting commences on August 19, 2026, and ends on September 17, 2026.

- Krsnaa Diagnostics provides the audio recording of its earnings conference call for the quarter ended June 30, 2026, held on August 14, 2026. - The recording is available on the company's website.

- Q1 FY27 Consolidated Revenue ₹2,355Mn vs ₹1,930Mn (▲22% YoY) - EBITDA ₹588Mn vs ₹524Mn (▲12% YoY) - PAT ₹166Mn vs ₹205Mn (▼19% YoY) - EBITDA Margin 25% vs 27% (▼221bps)

- Q1 FY27 Consolidated Revenue ₹235.5Cr vs ₹193.0Cr (▲22% YoY) - EBITDA ₹58.8Cr vs ₹52.4Cr (▲12% YoY) - PAT ₹16.6Cr vs ₹20.5Cr (▼19% YoY) - EBITDA Margin 25% vs 27% (▼200bps) - Revenue growth driven by established business and newly commissioned projects. - Rajasthan pathology network became operational, contributing ₹25.7 Cr revenue in Q1. - PAT and EBITDA margin contracted due to upfront fixed costs for new Rajasthan operations ahead of full utilisation. - Retail revenue grew 64% YoY to ₹19.3 Cr, expanding to over 4,250 touchpoints. - Board approved preferential warrant issue to Promoter and Promoter Group, reaffirming confidence.

- Q1 FY27 Consolidated Revenue ₹235.53Cr vs ₹192.98Cr (▲22.05% YoY) - EBITDA ₹57.99Cr vs ₹51.40Cr (▲12.80% YoY) - PAT ₹16.55Cr vs ₹20.52Cr (▼19.43% YoY) - EBITDA Margin 24.62% vs 26.63% (▼201bps) - Board recommended a final dividend of INR 2.00 per equity share for FY 2024-25. - Board approved issuance of 1,621,000 share warrants to promoter group at a price not less than INR 565/-. - Company received income tax demand of ₹626.90 million for multiple assessment years (AY 2017-18 to 2023-24) due to search and seizure proceedings. Company has filed appeals.

- Q1 FY27 Consolidated Revenue ₹2,355.32Mn vs ₹1,929.78Mn (▲22.05% YoY) - EBITDA ₹579.85Mn vs ₹514.04Mn (▲12.80% YoY) - PAT ₹165.51Mn vs ₹205.20Mn (▼19.34% YoY) - EBITDA Margin 24.62% vs 26.63% (▼201bps) - The Board recommended a final dividend of INR 2.00/- per equity share for FY 2024-25, with a record date of September 18, 2026. - The 16th AGM will be held on Monday, September 28, 2026, at 11:00 Hrs. (IST) in Physical Mode. - Approved the issuance of 1,621,000 share warrants to promoter/promoter group at an issue price higher of the floor price or Rs. 565/-. - Income Tax Authorities issued assessment orders for AY 2017-18 to AY 2023-24 for undisclosed income and disallowance of deductions, resulting in a demand of ₹626.90Mn. The company has filed appeals and deposited ₹102.77Mn under protest, with management believing the impact will not be material.

- Q1 FY27 Consolidated Revenue ₹235.53 Cr vs ₹192.98 Cr (▲22.05% YoY) - EBITDA ₹57.99 Cr vs ₹51.40 Cr (▲12.80% YoY) - PAT ₹16.55 Cr vs ₹20.52 Cr (▼19.34% YoY) - EBITDA Margin 24.62% vs 26.63% (▼201bps) - Board recommended a final dividend of INR 2.00/- per equity share for FY 2024-25. - The 16th Annual General Meeting (AGM) will be held on Monday, September 28, 2026, at 11:00 Hrs (IST) in Physical Mode. - Approved issuance of 1,621,000 share warrants to Promoter and Promoter Group at an issue price higher than INR 565/-. - Income Tax authorities issued demand orders of INR 62.69 Cr for various assessment years due to undisclosed income and disallowances from search proceedings. The company has filed appeals against these orders.

- Q1 FY27 Consolidated Revenue ₹2,355.32Mn vs ₹1,929.78Mn (▲22.05% YoY) - EBITDA ₹579.80Mn vs ₹513.96Mn (▲12.81% YoY) - PAT ₹165.51Mn vs ₹205.20Mn (▼19.47% YoY) - EBITDA Margin 24.62% vs 26.63% (▼201bps) - Notice of the 16th AGM on September 28, 2026, at 11:00 Hrs (IST). Final dividend of INR 2.00/- per share for FY 2024-25 recommended, with September 18, 2026, as record date. - Board approved issuance of 1,621,000 share warrants to promoter group at an issue price higher of floor price or Rs. 565/-. - Company received demand order of INR 626.90 million from Income Tax authorities following search proceedings (AY 2017-18 to AY 2023-24). Appeals filed, INR 102.77 million deposited under protest. Management views impact as immaterial.

- Q1 FY27 Consolidated Operating Revenue ₹235.53 Cr vs ₹192.98 Cr (▲22.05% YoY) - EBITDA ₹57.99 Cr vs ₹51.40 Cr (▲12.80% YoY) - PAT ₹16.55 Cr vs ₹20.52 Cr (▼19.44% YoY) - EBITDA Margin 24.62% vs 26.64% (▼202bps) - A final dividend of INR 2.00/- per share for FY 2024-25 was recommended. - Board approved preferential issuance of 1,621,000 share warrants to Promoter and Promoter Group at a floor price of INR 565/-. - The 16th AGM is scheduled for Monday, September 28, 2026, at 11:00 Hrs (IST). - Income Tax Authorities issued a demand order of INR 626.90 Mn for undisclosed income and disallowed deductions following search and seizure proceedings. The company has filed appeals.

New Filing detected. See link for details.

- Order Win: Krsnaa Diagnostics Limited entered into a Public Private Partnership (PPP) Agreement with the Director Health Services, Health & Family Welfare Department, Government of Himachal Pradesh. - Project Scope: To set up, operate, manage, maintain, and report CT Scan Diagnostic Facilities at 34 Government Health Institutions, expanding from the previous 12 institutions. - Project Duration: Initial period of seven years, extendable by a further three years. - Order Value: Not estimable as it is a new project.

- Krsnaa Diagnostics Ltd. announced the passing of all four special resolutions via Postal Ballot on July 04, 2026. These include the re-appointment of Mr. Chetan Desai and appointment of Mr. Raju Venkatraman and Ms. Lilian Jessie Paul as Independent Directors, and approval of their remuneration.

- ICRA Limited reaffirmed the long-term rating of ICRA A (Stable) and short-term rating of ICRA A1 for Krsnaa Diagnostics' ₹304.15 Cr bank facilities. - The outlook on the long-term rating is Stable.

- Trading window for Krsnaa Diagnostics Ltd. closed from July 01, 2026. - It will reopen 48 hours after the declaration of unaudited financial results for the quarter ending June 30, 2026. - Applies to Directors, KMP, Designated Employees, Promoters, and their relatives to prevent insider trading.